2nd National Melanoma Conference
10 & 11 October 2014, Rendezvous Hotel, Perth
Thursday, 9 October 2014
12.00pm – 5.00pm
5.30pm – 7.30pm
ANZMTG AGM + ASM
Harry Perkins Institute of Medical Research
Room: G24
Welcome Reception
Harry Perkins Institute of Medical Research
Room: Leedman’s Leap
Friday, 10 October 2014
8.00am – 9.00am
9.00am – 9.15am
9.15am – 10.35am
9.15am
9.45am
10.15am
Registration Opens
Rendezvous Hotel, Grand Ballroom East
Welcome and Opening Address
Ms Lisa Scaffidi, The Right Honourable the Lord Mayor of Perth
SESSION ONE: Combination Therapies and Molecular Markers
Session Chair: Professor Peter Leedman
Convergent de-differentiation during intra-patient evolution in therapy naïve
melanoma
Professor Mark Shackleton
Peter MacCallum Cancer Centre, Vic
Inability to cell cycle arrest in response ATM checkpoint signaling is a
common feature of melanomas
Professor Brian Gabrielli
UQ/Diamantina Institute, Qld
Targeting Rab27a to suppress melanoma proliferation and invasion
Dr Kim Beaumont
Centenary Institute, NSW
10.35am – 11.00am
Morning Tea – Grand Ballroom West
11.00am – 11.45am
SESSION TWO: Grand Ballroom East: Insights into Melanoma Biomarkers
Session Chair: Professor Mark Shackleton
Keynote Lecture
Understanding the biology of melanocytes and melanoma cells to develop new
strategies for therapy
Professor Meenhard Herlyn
Molecular and Cellular Oncogenesis; Director for Translational Research,
Wistar Institute Cancer Centre, Phil. USA
Lunch + Poster Session – Grand Ballroom West
11.00am
11.45am – 12.45pm
12.45pm – 2.15pm
12.45pm
1.15pm
1.45pm
SESSION THREE: Grand Ballroom East: Epidemiology and Early Diagnosis
Session Chair: Professor Charles Balch
Professor Graham Mann
Chair, University of Sydney Cancer Research Network
Co-Director, Centre for Cancer Research | Westmead Millennium Institute
Research Director | Melanoma Institute Australia
Diagnosis, initial treatment and supportive care needs of adults with localised
melanoma in Queensland: The Primary Melanoma Project
Professor Adele Green
QIMR Berghofer Medical Research Institute Qld
The genetic architecture of melanoma susceptibility
Professor Nick Hayward
QIMR Berghofer Medical Research Institute Qld
2.15pm – 3.10pm
SESSION FOUR: Signalling pathways, cellular resistance & novel treatments
2.15pm
Dual Targeting the MAPK/ERK and CDK4 Pathways in Melanoma Induces
Sustained Tumor Regression
Page 1 of 3
2.35pm
2.50pm
3.10pm - 3.40pm
3.40pm – 4.40pm
3.40pm
3.55pm
4.10pm
4.25pm
4.40pm
6.00pm - 7.00pm
7.00pm – 11.30pm
Dr Karen Sheppard
Peter MacCallum Cancer Centre
A systems biology approach identifies synergistic drug-immunotherapy
combinations
Dr Joost Lesterhuis
University of Western Australia
Melanoma cells in G1 phase escape proteasome inhibitor cytotoxicity
A/Prof Nikolas Haass
University Of Queensland Diamantina Institute/Translational Research Institute
Afternoon Tea – Grand Ballroom West
SESSION FIVE: Grand Ballroom East: SKMRC Discovery Grant Recipients
Session Chair: Professor Adele Green
MicroRNA-7-5p suppresses melanoma metastasis by inhibiting insulin receptor
substrate-2 expression and NF-B signalling
Dr Keith Giles
New York University, NY, USA
Vemurafenib treatment selects for melanoma cells expressing the
ABCB5-transporter
Dr Elin Gray
Edith Cowan University, WA
A novel immune component of the susceptibility formula for melanoma
Dr Prue Hart
Telethon Kids Institute, WA
Genetic Predictors of Melanoma Outcomes
Professor Grant Morahan
UWA/Perkins Institute, WA
Close
Wine Tasting - Guided Session
Conference Dinner – Mentelle Room, Rendezvous Grand Hotel
7pm Pre dinner drinks
Saturday, 11 October 2014
7.30am – 8.00am
7.30am - 10.00am
8.00am – 9.00am
9.00am – 1000am
10.15am – 12.40pm
10.15am
11.00am
11.25am
11.50am
Registration
Melanoma Consumer Forum - Supported by MelanomaWA
Rendezvous Hotel, Preston Room (B&C)
Session Chair: Dr Mark Lee
Professor Charles Balch, Professor Michael Millward, Ms Karen Anderson
Workshop Session and Panel Discussion
SESSION SIX: Surgical and Clinical Advances in Melanoma
Session Chair: Professor John Thompson
Keynote Lecture
Staging and Surgical Management of Melanoma
Professor Charles Balch
Professor of Surgery, Division of Surgical Oncology, University of Texas
Southwestern Medical Center
The important, continuing roles of surgery and loco-regional treatments in melanoma
management in the era of more effective systemic therapies
Professor John Thompson
Melanoma Institute Australia, NSW
Paediatric Melanoma in Western Australia
Dr Mark Lee
UWA/SJOGH, WA
Surgical and Clinical Advances in Melanoma
Professor Michael Millward
UWA/SCGH, WA
Page 2 of 3
12.15pm
12.40pm – 1.30pm
1.30pm – 2.45pm
1.30pm
2.15pm
2.30pm
2.45pm - 3.15pm
3.15pm – 4.30 pm
3.15pm
3.30pm
3.45pm
4.00pm
4.15pm
4.30pm
Melanoma Biomarkers in the Molecular era
Professor Richard Scolyer
Melanoma Institute Australia, NSW
Lunch – Grand Ballroom West
SESSION SEVEN: Grand Ballroom East:
Session Chair: Professor Richard Scolyer
Keynote Lecture
Primary overall survival (OS) from OPTiM, a randomised phase III trial of talimogene
laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colonystimulating factor (GM-CSF) for the treatment of unresected stage IIIB/C and IV
melanoma
Professor Robert Andtbacka
University of Utah, USA
Session Sponsored by Amgen Australia
PET CT in Melanoma
Dr Louise Emmett
St Vincent’s Hospital, NSW
Emerging Radiotherapy Techniques in The Management of Melanoma
Dr Bryan Burmeister
Princess Alexandra Hospital, Qld
Afternoon Tea
ANZMTG Trial update
Session Chair: Professor Bryan Burmeister
ANZMTG 01.14 ABC Nivo trial - A phase II study of nivolumab and nivolumab in
combination with ipilimumab in patients with melanoma brain metastases. Presented
by Associate Professor Georgina Long
ANZMTG 02.14 CombiRT trial - An open-label, single-arm, phase I/II, multicentre study
to evaluate the safety and efficacy of the combination of dabrafenib, trametinib and
palliative radiotherapy in patients with unresectable (stage IIIc) and metastatic (stage
IV) BRAF V600E/K mutation- positive cutaneous melanoma. Presented by Dr Tim
Wang
ANZMTG 01.12 EAGLE FM trial – Evaluation of Groin Lymphadenectomy Extent For
metastatic Melanoma; A randomised phase III trial investigating Inguinal or Ilio-inguinal
Lymphadenectomy for patients with metastatic melanoma to groin lymph nodes with no
evidence of pelvic disease on PET/CT Scan. Presented by Libby Paton on behalf of
Associate Professor Andrew Spillane
ANZMTG 03.12 Melanoma Margins Trial (MelMarT) Trial: A Phase III, multi-centre,
multi-national randomised control trial investigating 1cm v 2cm wide excision margins
for primary cutaneous melanoma. Presented by Professor Michael Henderson on
behalf of Dr Marc Moncrieff
ANZMTG 02.12 Radiotherapy or Imiquimod observed with Confocal microscopy in
lentigo mALigna (RADICAL) Trial; A Phase III trial of imiquimod vs radiotherapy for
lentigo maligna mapped with reflectance confocal microscopy. Presented by Associate
Professor Gerald Fogarty on behalf of Dr Pascale Guitera
Conference wrap up and Close
Page 3 of 3